Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | TK1 | P04183 | 6/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16127042 | 1.00 | BCHE (0.56) | BCHETK1LMNATSHRALB | |
| Phosphoric Acid SCHEMBL18107895 | 0.94 | TK1 (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL26195062 | 0.88 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL1878103 | 0.88 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL21246468 | 0.88 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL25708175 | 0.88 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL3611845 | 0.88 | BCHE (0.55) | BCHETK1LMNATSHRALB | |
| SCHEMBL2633814 | 0.88 | BCHE (0.52) | BCHETK1LMNATSHRALB | |
| SCHEMBL24500263 | 0.86 | BCHE (0.53) | BCHETK1LMNATSHRALB | |
| SCHEMBL18020480 | 0.86 | BCHE (0.53) | BCHETK1LMNATSHRALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635467-B2 | Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2009-12-22 | — | — | US | claimed |
| US-7618621-B2 | Mammalian multipotent neural stem cells and compositions, methods of preparation and methods of administration thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2009-11-17 | — | — | US | claimed |
| US-20230173079-A1 | Conjugate Molecules | DIVERSE BIOTECH, INC. (US) | 2023-06-08 | — | — | US | disclosed |
| US-20210123054-A1 | OLIGONUCLEOTIDES FOR MODULATING TAU EXPRESSION | ROCHE INNOVATION CENTER COPENHAGEN A/S (DK) | 2021-04-29 | — | — | US | disclosed |
| WO-2021020562-A1 | PRIMER, DEVICE FOR PRODUCING DOUBLE-STRANDED DNA USING SAME, AND METHOD FOR PRODUCING DOUBLE-STRANDED DNA | 国立研究開発法人科学技術振興機構 | 2021-02-04 | — | — | WO | disclosed |
| US-10519446-B2 | Organic compounds to treat hepatitis B virus | NOVARTIS AG (CH) | 2019-12-31 | — | — | US | disclosed |
| EP-3052627-B1 | NOVEL FORMATS FOR ORGANIC COMPOUNDS FOR USE IN RNA INTERFERENCE | NOVARTIS AG (CH) | 2018-08-22 | — | — | EP | disclosed |
| US-9988627-B2 | Formats for organic compounds for use in RNA interference | NOVARTIS AG (CH) | 2018-06-05 | — | — | US | disclosed |
| EP-3052107-B1 | ORGANIC COMPOUNDS TO TREAT HEPATITIS B VIRUS | NOVARTIS AG (CH) | 2018-05-02 | — | — | EP | disclosed |
| EP-2928876-B1 | NUCLEOSIDE KINASE BYPASS COMPOSITIONS AND METHODS | MERCK SHARP & DOHME (US) | 2018-01-17 | — | — | EP | disclosed |
| US-9624249-B2 | Nucleoside kinase bypass compositions and methods | MERCK SHARP & DOHME CORP. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20100183567-A1 | Novel Mammalian Multipotent Stem Cells and Compositions, Methods of Preparation and Methods of Administration Thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2010-07-22 | — | — | US | disclosed |
| US-7635467-B2 | Mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2009-12-22 | — | — | US | disclosed |
| US-7618621-B2 | Mammalian multipotent neural stem cells and compositions, methods of preparation and methods of administration thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1471970-A4 | NOVEL MAMMALIAN MULTIPOTENT STEM CELLS AND COMPOSITIONS, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION THEREOF | UNIV ILLINOIS (US) | 2006-08-02 | — | — | EP | disclosed |
| EP-1471970-A2 | NOVEL MAMMALIAN MULTIPOTENT STEM CELLS AND COMPOSITIONS, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION THEREOF | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20030219898-A1 | Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-11-27 | — | — | US | disclosed |
| US-20030148513-A1 | Novel mammalian multipotent neural stem cells and compositions, methods of preparation and methods of administration thereof | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2003-08-07 | — | — | US | disclosed |
| WO-2003060085-A2 | MAMMALIAN NEURAL STEM CELLS, COMPOSITIONS AND USES THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059276-A2 | NOVEL MAMMALIAN MULTIPOTENT STEM CELLS AND COMPOSITIONS, METHODS OF PREPARATION AND METHODS OF ADMINISTRATION THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173079-A1 | Conjugate Molecules | CNR2, CNR1, MAG | BCHE 493/4885TK1 2613/4885LMNA 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.